How is venture philanthropy revolutionizing Alzheimer's drug discovery? We sit down with Karen Harris, CFO at the Alzheimer's Drug Discovery Foundation, to explore their game-changing approach to funding early-stage research.

With $370M+ awarded to 765+ programs globally, the ADDF operates like a VC firm—using convertible debt and preferred equity to accelerate breakthrough treatments.

Topics:

Venture philanthropy vs traditional grants

Shift from amyloid to combination therapies

Blood-based biomarkers & precision medicine

NIH funding cuts impact on research ecosystem

Karen brings 20+ years investment banking experience to discuss how strategic capital is changing Alzheimer's research.